KIN-1148 | CAS#1428729-56-9 | IRF3 agonist

MedKoo Cat#: 555218 | Name: KIN-1148

Description:

WARNING: This product is for research use only, not for human or veterinary use.

KIN-1148 is a IRF3 agonist. IN1148 induced dose-dependent IRF3 nuclear translocation and specific activation of IRF3-responsive promoters. Prime-boost immunization of mice with a suboptimal dose of a monovalent pandemic influenza split virus H1N1 A/California/07/2009 vaccine plus KIN1148 protected against a lethal challenge with mouse-adapted influenza virus (A/California/04/2009) and induced an influenza virus-specific IL-10 and Th2 response by T cells derived from lung and lung-draining lymph nodes.

Chemical Structure

KIN-1148

CAS#1428729-56-9

Theoretical Analysis

MedKoo Cat#: 555218

Name: KIN-1148

CAS#: 1428729-56-9

Chemical Formula: C19H11N3OS2

Exact Mass: 361.0344

Molecular Weight: 361.44

Elemental Analysis: C, 63.14; H, 3.07; N, 11.63; O, 4.43; S, 17.74

Price and Availability

Size	Price	Availability
50mg	USD 650.00	2 Weeks
100mg	USD 1,050.00	2 Weeks
200mg	USD 1,650.00	2 Weeks
500mg	USD 2,150.00	2 Weeks
1g	USD 3,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

KIN-1148; KIN 1148; KIN1148.

IUPAC/Chemical Name

N-(benzo[1,2-d:3,4-d']bis(thiazole)-2-yl)-2-naphthamide

InChi Key

YAISOECYKYATLL-UHFFFAOYSA-N

InChi Code

InChI=1S/C19H11N3OS2/c23-18(13-6-5-11-3-1-2-4-12(11)9-13)22-19-21-14-7-8-15-16(17(14)25-19)20-10-24-15/h1-10H,(H,21,22,23)

SMILES Code

O=C(NC1=NC2=CC=C(SC=N3)C3=C2S1)C4=CC=C5C=CC=CC5=C4

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

KIN1148, a small-molecule IRF3 agonist, is a novel influenza vaccine adjuvant found to enhance flu vaccine efficacy.

In vitro activity:

KIN1148 induced dose-dependent IRF3 nuclear translocation and specific activation of IRF3-responsive promoters. Reference: Vaccine. 2017 Apr 4;35(15):1964-1971. https://pubmed.ncbi.nlm.nih.gov/28279563/

In vivo activity:

Prime-boost immunization of mice with a suboptimal dose of a monovalent pandemic influenza split virus H1N1 A/California/07/2009 vaccine plus KIN1148 protected against a lethal challenge with mouse-adapted influenza virus (A/California/04/2009) and induced an influenza virus-specific IL-10 and Th2 response by T cells derived from lung and lung-draining lymph nodes. Reference: Vaccine. 2017 Apr 4;35(15):1964-1971. https://pubmed.ncbi.nlm.nih.gov/28279563/

	Solvent	mg/mL	mM
Solubility
	DMSO	55.3	152.86

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 361.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Probst P, Grigg JB, Wang M, Muñoz E, Loo YM, Ireton RC, Gale M Jr, Iadonato SP, Bedard KM. A small-molecule IRF3 agonist functions as an influenza vaccine adjuvant by modulating the antiviral immune response. Vaccine. 2017 Apr 4;35(15):1964-1971. doi: 10.1016/j.vaccine.2017.01.053. Epub 2017 Mar 6. PMID: 28279563.

In vitro protocol:

In vivo protocol:

1: Probst P, Grigg JB, Wang M, Muñoz E, Loo YM, Ireton RC, Gale M Jr, Iadonato SP, Bedard KM. A small-molecule IRF3 agonist functions as an influenza vaccine adjuvant by modulating the antiviral immune response. Vaccine. 2017 Apr 4;35(15):1964-1971. doi: 10.1016/j.vaccine.2017.01.053. Epub 2017 Mar 6. PubMed PMID: 28279563.